Hypertension Management
The management of hypertension should begin with lifestyle modifications for all patients, followed by pharmacological therapy with ACE inhibitors/ARBs, calcium channel blockers, or thiazide diuretics as first-line medications when BP targets are not achieved, with most patients requiring at least two medications to reach their goal. 1
Diagnosis and Classification
- Blood pressure should be measured using properly calibrated equipment, with the patient seated and arm at heart level, after 5 minutes of rest, taking at least two measurements per visit 1
- Hypertension classification:
- Normal BP: <120/80 mmHg
- Elevated BP (Prehypertension): 120-129/<80 mmHg
- Stage 1 Hypertension: 130-139/80-89 mmHg
- Stage 2 Hypertension: ≥140/90 mmHg
- Hypertensive Crisis: >180/120 mmHg 1
Treatment Targets
- General population: ≤140/90 mmHg
- High-risk patients (diabetes, renal impairment, cardiovascular disease): ≤130/80 mmHg
- Elderly patients (>80 years): Consider initiating treatment only when office SBP ≥160 mmHg 2, 1
Lifestyle Modifications
Lifestyle modifications are the cornerstone for prevention and treatment of hypertension for all patients 2, 1:
Dietary approaches:
- DASH diet or Mediterranean diet (3-11 mmHg reduction)
- Sodium reduction (3-6 mmHg reduction)
- Enhanced potassium intake (3-5 mmHg reduction)
Physical activity:
- 150 minutes of moderate aerobic exercise weekly
- 30-60 minutes of moderate exercise 4-7 days/week (3-8 mmHg reduction)
Weight management:
- Weight loss for overweight/obese patients (1 mmHg reduction per kg lost)
Alcohol moderation:
- Limit to ≤2 drinks daily (maximum 14/week for men, 9/week for women)
- Can reduce BP by 3-4 mmHg
Smoking cessation:
- Strongly recommended to reduce overall cardiovascular risk 1
Pharmacological Therapy
First-Line Medications
- ACE inhibitors (e.g., lisinopril)
- ARBs (e.g., losartan)
- Calcium channel blockers (e.g., amlodipine)
- Thiazide or thiazide-like diuretics (e.g., hydrochlorothiazide, chlorthalidone) 1, 3
Treatment Algorithm
Initial therapy:
- Start with a single agent at a low dose
- For non-black patients: Low-dose ACE inhibitor/ARB
- For black patients: Low-dose ARB + dihydropyridine CCB or dihydropyridine CCB + thiazide-like diuretic 1
Combination therapy:
Resistant hypertension:
Special Populations
Diabetes
- Target BP: <130/80 mmHg
- Preferred regimen: RAS inhibitor (ACE inhibitor/ARB) + CCB and/or thiazide-like diuretic 1
- Losartan is specifically indicated for diabetic nephropathy with elevated serum creatinine and proteinuria 4
Heart Failure
- Target BP: <130/80 mmHg but >120/70 mmHg
- Preferred regimen: RAS blockers, beta-blockers, and mineralocorticoid receptor antagonists 1
- Lisinopril is indicated to reduce signs and symptoms of systolic heart failure 5
Left Ventricular Hypertrophy
- Losartan is indicated to reduce stroke risk in patients with hypertension and LVH
- Note: This benefit may not apply to Black patients 4
Elderly Patients
- Start with lower medication doses
- Titrate slowly to avoid orthostatic hypotension
- Lower BP gradually to avoid complications 1
Pregnancy
- ACE inhibitors and ARBs are contraindicated
- Preferred medications: methyldopa, labetalol, or nifedipine 1
Monitoring and Follow-up
- Monitor every 2-4 weeks until BP goal is achieved, then every 3-6 months
- Routine investigations: urine strip test, blood electrolytes and creatinine, blood glucose, lipid profile, and ECG
- Allow at least four weeks to observe full response to medication changes 1
Common Pitfalls to Avoid
Underestimating the importance of lifestyle modifications - These interventions can significantly reduce BP and enhance medication efficacy 2, 1, 7
Inadequate dosing or insufficient number of medications - Most patients require at least two medications to reach target BP 1, 4, 5
Not considering patient-specific factors - Age, ethnicity, and comorbidities should guide medication selection 1
Poor medication adherence - Consider single-pill combinations to improve compliance 6
Failure to screen for secondary causes - Particularly important in young adults (<40 years) and resistant hypertension 1, 6